Pinos Elisabet de Los files SEC Form 4 disclosures for Aura Biosciences, Inc.. They have made 9 open-market trades across 1 company since 2022, most recently 2026-03-02.
CIK 0001889633
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AURA | 575,815 | $3.8M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AURA | SELL | 2026-02-17 | 2026-02-17 | $5.06 | $241K | +12.6% | +25.8% | +43.0% |
| AURA | SELL | 2026-01-20 | 2026-01-20 | $4.86 | $82K | +12.7% | +7.8% | +41.9% |
| AURA | SELL | 2025-10-29 | 2025-10-29 | $6.35 | $115K | -9.4% | +8.4% | -7.1% |
| AURA | SELL | 2025-02-18 | 2025-02-18 | $7.75 | $313K | -3.4% | -4.3% | -23.6% |
| AURA | SELL | 2025-01-21 | 2025-01-21 | $7.67 | $245K | -0.5% | -3.3% | -29.4% |
| AURA | SELL | 2024-10-29 | 2024-10-29 | $10.74 | $99K | +3.6% | -11.3% | -23.9% |
| AURA | SELL · 10b5-1 | 2024-10-18 | 2024-10-18 | $12.04 | $602K | -13.0% | -23.3% | -35.6% |
| AURA | SELL | 2024-01-23 | 2024-01-24 | $7.64 | $242K | +2.9% | +17.7% | -4.4% |
| AURA | SELL · 10b5-1 | 2023-11-06 | 2023-11-07 | $12.03 | $179K | +6.9% | +13.9% | +2.5% |
| AURA | SELL | 2023-10-30 | 2023-11-01 | $6.83 | $131K | -14.5% | -9.7% | -10.5% |
| AURA | SELL | 2022-10-31 | 2022-11-02 | $12.46 | $142K | +6.4% | +7.1% | -15.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.